The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is … Continue reading "Tecentriq® Approved for Bladder Cancer"
The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Bladder cancer will be diagnosed in approximately 77,000 people in … Continue reading "Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer"